In the past decade, five oral nucleos(t)ide analogs and two formulations of pegylated interferon alpha have been approved for the treatment of chronic hepatitis B (CHB). Due to low personal income and inadequate health care system, low-to-moderate genetic barrier antiviral drugs are still widely used in China, which brings increased suboptimal response, viral relapse and resistance in reallife clinical practice. Combination therapy is a relative good approach to deal with these dilemma in Chinese CHB patients, and the strategies include de novo combination, rescue combination therapy, and optimized combination therapy. At present, combination therapy could be sonsidered for those who have suboptimal response to antiviral drugs, at high risk of complications in the event of virological breakthrough/rebound, or already with drug-resistant hepatitis B virus infection.
Published on: Aug 28, 2015 Pages: 1-4